Kate Yen, Auron Therapeutics founder and CEO

Armed with a $48M Se­ries A, Au­ron is look­ing to ap­ply ma­chine learn­ing in can­cer treat­ment

The hype of ma­chine learn­ing has man­aged to bag se­ri­ous cash from in­vestors over the past year, and the lat­est biotech to en­ter the for­ay is look­ing to ap­ply it to can­cer.

Mass­a­chu­setts-based Au­ron Ther­a­peu­tics fo­cus­es on ther­a­pies that tar­get dys­reg­u­lat­ed cells that can lead to tu­mors and can­cer.

Ac­cord­ing to Au­ron CEO and founder Kate Yen, the biotech is de­vel­op­ing ther­a­pies that tar­get dis­rupt­ed cel­lu­lar dif­fer­en­ti­a­tion. To do that it has built a pro­pri­etary ma­chine learn­ing and com­pu­ta­tion­al plat­form dubbed AU­Ri­gin. The plat­form al­lows it to in­te­grate mul­ti omics da­ta sets from both nor­mal hu­man tis­sue and tu­mor sam­ples to help iden­ti­fy path­ways that are crit­i­cal for both nor­mal cel­lu­lar dif­fer­en­ti­a­tion and then how those path­ways have been hi­jacked by tu­mor cells.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.